UpStream Bio Inc. UPB 深 滬
等待開盤 10-01 09:30:00 美东时间
18.81
+1.470
+8.48%
華盛通- 最 高19.23
- 今 開17.34
- 成交量 78.30万股
- 最 低 17.14
- 昨 收 17.34
- 總市值 10.12亿
- 52周最高 29.4599
- 市盈率 靜 --
- 換手率 1.46%
- 52周最低 5.14
- 委 比 51.29%
- 總股本 5379.37万
- 歷史最高 29.4599
- 量 比 3.50
- 振 幅 12.05%
- 歷史最低 5.14
- 每 手 1
- 風險率 5.86%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Upstream Bio Highlights New Respiratory Drug Verekitug With Trial Data
Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today presented structural and mechanistic data showing
09-30 16:26
Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug’s Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress
Upstream Bio presented data on verekitug, a novel antibody targeting the TSLP receptor, showing its potent inhibition of TSLP receptor activity, rapid and sustained effects in patients with chronic rhinosinusitis, and potential for less frequent dosing compared to existing therapies. Verekitug demonstrated high affinity binding to the TSLP receptor, outcompeting TSLP and blocking its signaling, with Phase 2 data showing significant clinical benef...
09-30 08:15
Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum
Upstream Bio, Inc. (Nasdaq: UPB), a company developing treatments for inflammatory diseases with a focus on severe respiratory disorders, announced that CEO Rand Sutherland will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on September 15, 2025, at 10:30 a.m. ET. The event will be webcast live and available for replay on the Company's website. Upstream Bio is advancing verekitug, a monoclonal antibod...
09-09 11:00
美股牛股 | 医药股彻底疯狂！美国联合医疗飙升近33%，新药迎重大进展；Ionis制药涨近35%
医药股彻底疯狂！美国联合医疗飙升近33%，新药迎重大进展；Ionis制药涨近35%，实验性药物临床数据乐观；MLYS大涨逾80%，高血压新药市场前景广阔>>
09-03 15:53
Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage biotechnology company, announced that it will report top-line data from its Phase 2 VIBRANT trial of verekitug, a monoclonal antibody targeting TSLP receptor, on September 2, 2025. The VIBRANT trial assessed verekitug's efficacy and safety in adults with chronic rhinosinusitis with nasal polyps (CRSwNP), with the primary endpoint being the change in endoscopic nasal polyp score at Week 24. The co...
09-01 21:00
Two Harbors Investment to pay $375M to settle Pine River litigation
Two Harbors Investment (NYSE:TWO) agreed to pay $375M in cash to settle all litigation related to terminating its management agreement with PRCM Advisers LLC, Pine River Capital Management LP, and Pin...
08-21 04:40
Claros Mortgage Trust outlines $2B+ loan resolution trajectory while advancing REO strategies
Earnings Call Insights: Claros Mortgage Trust (CMTG) Q2 2025 Management View Richard Jay Mack, CEO, stated that while "the elevated rate environment remains a headwind for commercial real estate, we'r...
08-08 17:33
Upstream Bio, Inc. Reports Increased R&D Investments
Upstream Bio, Inc. ( ($UPB) ) has released its Q2 earnings. Here is a breakdown...
08-07 14:51
Upstream Bio, Inc. reports Q2 results
Upstream Bio, Inc. press release (NASDAQ:UPB): Q2 Revenue of $0.9M. Net loss was $40.0 million for the quarter ended June 30, 2025, compared to a net loss of $14.7 million for the same period in 2024....
08-06 19:48
Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress
Upstream Bio reported Q2 2025 financial results and highlighted recent business milestones. The company advanced Verekitug, a monoclonal antibody targeting TSLP receptor, in Phase 2 trials for chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD). Enrollment was completed in the severe asthma trial in June 2025, with top-line data expected in Q1 2026. The first patient was dosed in the ...
08-06 11:00
